APOE and dementia: While the low levels of AD biomarkers captured in our sample do not meet the cut-offs to predict cognitive decline or dementia (Blennow et al., 2019; Brum et al., 2022), our findings indicate that biomarker levels within this range may affect brain structure when considering additional contributing factors such as estrogens and APOE genotype.